Discovery and biological activity of a novel class i PI3K inhibitor, CH5132799

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 6, 2011, Pages 1767-1772

  Ohwada, Jun ^a   Ebiike, Hirosato ^a   Kawada, Hatsuo ^a   Tsukazaki, Masao ^a   Nakamura, Mitsuaki ^a   Miyazaki, Takuya ^a   Morikami, Kenji ^a   Yoshinari, Kiyoshi ^a   Yoshida, Miyuki ^a   Kondoh, Osamu ^a   Kuramoto, Shino ^a   Ogawa, Kotaro ^a   Aoki, Yuko ^a   Shimma, Nobuo ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Cancer; PI3K

Indexed keywords

ANTINEOPLASTIC AGENT; CH 5132799; PHENOL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLOPYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; IC 50; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; TUMOR XENOGRAFT;

CELL LINE, TUMOR; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; PHOSPHATIDYLINOSITOL 3-KINASES; PYRIMIDINES; SULFONAMIDES;

MUS;

EID: 79952359845     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.01.065     Document Type: Article

References (17)

1. P. Liu, H. Cheng, T.M. Roberts, and J.J. Zhao Nat. Rev. Drug Disc. 8 2009 627
2. A.G. Bader, S. Kang, L. Zhao, and P.K. Vogt Nat. Rev. Cancer 5 2005 921
3. D.P. Sutherlin, D. Sampath, M. Berry, G. Castanedo, Z. Chang, I. Chuckowree, J. Dotson, A. Folkes, L. Friedman, R. Goldsmith, T. Heffron, L. Lee, J. Lesnick, C. Lewis, S. Mathieu, J. Nonomiya, A. Olivero, J. Pang, W.W. Prior, L. Salphati, S. Sideris, Q. Tian, V. Tsui, N.C. Wan, S. Wang, C. Wiesmann, S. Wong, and B.Y. Zhu J. Med. Chem. 53 2010 1086
4. S. Yaguchi, Y. Fukui, I. Koshimizu, H. Yoshimi, T. Matsuno, H. Gouda, S. Hirono, K. Yamazaki, and T. Yamori J. Natl. Cancer Inst. 98 2006 545
5. S.M. Maira, F. Stauffer, J. Brueggen, P. Furet, C. Schnell, C. Fritsch, S. Brachmann, P. Chene, A. De Pover, K. Schoemaker, D. Fabbro, D. Gabriel, M. Simonen, L. Murphy, P. Finan, W. Sellers, and C. Garcia-Echeverria Mol. Cancer Ther. 7 7 2008 1851
6. A homology model of PI3Kα was constructed from the crystal structure of PI3K γ comlex with staurosporine (PDB:1E8Z).
7. free values of 0.241/0.315 at 2.9 resolution, 0.250/0.316 at 2.5, and 0.236/0.290 at 2.5, respectively.
8. Hayakawa, M.; Kaizawa, H.; Moritomo, H.; Kawaguchi, K.; Koizumi, T.; Yamano, M.; Matsuda, K.; Okada, M.; Ohta, M.; WO Patent, 1083456, 2001.
9. Nuss, J M.; Pecchi, S.; Renhowe, P A.; WO Patent, 4048365, 2004.
10. PDB ID code: 3APF
11. FlexX with the single interaction scan algorithm. R. Matthias, K. Bernd, L. Thomas, and K. Gerhard J. Mol. Biol. 261 1996 470
12. R. Matthias, W. Stephan, and L. Thomas J. Comput. Aided Mater. Des. 10 1996 41 Virtually synthesized compounds from 4-chloro-2-morpholin-4-yl-7- pyridin-4-yl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine and available boronic acids having hydrogen bond donor/acceptor were scored by FlexSIS docking simulations and compounds with high FlexSIS scores were actually synthesized by Suzuki coupling. For example, the score of 2-aminopyrimidine-5-yl was -25.5 kJ/mol, and this was more highly prioritized than indoline-5-yl (-21.5 kJ/mol). We are publishing these details in the near future. Filed patent: WO Patent, 018426, 2008 (Filing date: Aug, 8, 2006)
13. PDB ID code: 3APD
14. PDB ID code: 3APC
15. M.L. Quesada, and R.H. Schlessinger J. Org. Chem. 43 1978 346
16. Tanaka, H.; Yoshida, M.; Tanimura, H.; Fujii, T.; Sakata, K.; Tachibana, Y.; Ohwada, J.; Ebiike, H.; Kuramoto, S.; Morita, K.; Yoshimura, Y.; Yamazaki, T.; Ishii, N.; Kondoh, O.; Aoki, Y. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations; Clin. Cancer Res., in press.
17. J. Kurebayashi, T. Otsuki, C.K. Tang, M. Kurosumi, S. Yamamoto, K. Tanaka, M. Mochizuki, H. Nakamura, and H. Sonoo Br. J. Cancer 79 1999 707